
VRXA P/E Ratio
P/E Ratio as of Jun 12, 2026: 93.37
Average104.55
Median104.55
Minimum93.37
Maximum115.73
93.37
The P/E ratio for VRXA is 93.37 as of Jun 12, 2026. This represents a increase of 868.57% compared to its 12-month average P/E ratio of 9.64. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Veraxa Biotech AG P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Veraxa Biotech AG’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Veraxa Biotech AG to industry peers.
Veraxa Biotech AG P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Veraxa Biotech AG’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Veraxa Biotech AG to industry peers.
VRXA P/E Ratio Insights
See Veraxa Biotech AG’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in VRXA
Order type
Buy in
Order amount
Est. shares
0 shares
VRXA P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 11, 2026 | $24.79 | 115.73 |
VRXA End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | 93.37 | — |
FAQs About Veraxa Biotech AG (VRXA) P/E ratio
The latest P/E ratio of VRXA is 93.37, as of Jun 12, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Veraxa Biotech AG’s last 12-month average P/E ratio is 9.64, compared to its current P/E ratio of 93.37. This reflects a increase of 868.57%.
Veraxa Biotech AG’s current P/E ratio of 93.37 is higher than its last 12-month average P/E of 9.64. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Veraxa Biotech AG’s average P/E ratio over the last 3 years is 3.21. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Veraxa Biotech AG’s average P/E ratio over the last 5 years is 1.93. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.